United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension; and a licensing and commercialization agreement with Collplant for 3D bioprinting of solid-organ scaffolds for human transplants. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone301-608-9292
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.73 billion
Profitability
Miscellaneous
Employees800
OptionableOptionable
United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions
What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
How will United Therapeutics' stock buyback program work?
United Therapeutics declared that its board has authorized a stock repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 4.6% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
How were United Therapeutics' earnings last quarter?
United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, October, 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $3.23 by $0.81. The biotechnology company earned $412.70 million during the quarter, compared to analysts' expectations of $378.22 million. United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. The firm's quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.69 earnings per share. View United Therapeutics' Earnings History.
When is United Therapeutics' next earnings date?
What price target have analysts set for UTHR?
8 brokerages have issued 12-month price targets for United Therapeutics' stock. Their forecasts range from $95.00 to $253.00. On average, they expect United Therapeutics' stock price to reach $135.00 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View Analyst Price Targets for United Therapeutics.
What is the consensus analysts' recommendation for United Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.
What are Wall Street analysts saying about United Therapeutics stock?
Here are some recent quotes from research analysts about United Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%." (11/1/2018)
- 2. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. The acquisition of SteadyMed added its drug device pipeline product Trevyent to its portfolio, which could have posed competition to Implantable System for Remodulin (ISR) which was approved recently in July with a launch scheduled for 2019. However, competition in the PAH market is increasing. Also two of its biggest products - Remodulin and Adcirca – are expected to face generic competition this year. United Therapeutics’ shares have also underperformed the industry so far this year." (10/22/2018)
Has United Therapeutics been receiving favorable news coverage?
Press coverage about UTHR stock has trended positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of United Therapeutics' key competitors?
Some companies that are related to United Therapeutics include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS) and Jazz Pharmaceuticals (JAZZ).
Who are United Therapeutics' key executives?
United Therapeutics' management team includes the folowing people:
- Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
- Mr. Michael I. Benkowitz, Pres & COO (Age 46)
- Mr. James C. Edgemond, CFO & Treasurer (Age 50)
- Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Kevin Gray, Sr. VP of Strategic Operations & Logistics
Who are United Therapeutics' major shareholders?
United Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Greylin Investment Mangement Inc. (0.28%), Denali Advisors LLC (0.21%), Retirement Systems of Alabama (0.13%), Nisa Investment Advisors LLC (0.04%), DNB Asset Management AS (0.04%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own United Therapeutics stock include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.
Which major investors are selling United Therapeutics stock?
UTHR stock was sold by a variety of institutional investors in the last quarter, including Sterling Investment Advisors Ltd., Legacy Financial Advisors Inc., Meeder Asset Management Inc. and Louisiana State Employees Retirement System. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.
Which major investors are buying United Therapeutics stock?
UTHR stock was purchased by a variety of institutional investors in the last quarter, including Greylin Investment Mangement Inc., Denali Advisors LLC, DNB Asset Management AS, First Citizens Bank & Trust Co., Nisa Investment Advisors LLC and Retirement Systems of Alabama. View Insider Buying and Selling for United Therapeutics.
How do I buy shares of United Therapeutics?
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is United Therapeutics' stock price today?
One share of UTHR stock can currently be purchased for approximately $115.75.
How big of a company is United Therapeutics?
United Therapeutics has a market capitalization of $5.05 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.
What is United Therapeutics' official website?
How can I contact United Therapeutics?
United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]
MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
